331 related articles for article (PubMed ID: 20225766)
21. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
[TBL] [Abstract][Full Text] [Related]
22. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
23. Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein.
Bryden H; MacKenzie J; Andrew L; Alexander FE; Angus B; Krajewski AS; Armstrong AA; Gray D; Cartwright RA; Kane E; Wright DH; Taylor P; Jarrett RF
Int J Cancer; 1997 Aug; 72(4):614-8. PubMed ID: 9259400
[TBL] [Abstract][Full Text] [Related]
24. Human immunodeficiency virus-associated Hodgkin's disease contains latent, not replicative, Epstein-Barr virus.
Siebert JD; Ambinder RF; Napoli VM; Quintanilla-Martinez L; Banks PM; Gulley ML
Hum Pathol; 1995 Nov; 26(11):1191-5. PubMed ID: 7590691
[TBL] [Abstract][Full Text] [Related]
25. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
26. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
27. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
28. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander.
Oudejans JJ; Jiwa NM; Meijer CJ
J Pathol; 1997 Apr; 181(4):353-6. PubMed ID: 9196428
[TBL] [Abstract][Full Text] [Related]
30. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
[TBL] [Abstract][Full Text] [Related]
31. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
32. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.
Yang J; Lemas VM; Flinn IW; Krone C; Ambinder RF
Blood; 2000 Jan; 95(1):241-8. PubMed ID: 10607708
[TBL] [Abstract][Full Text] [Related]
33. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
34. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
Fogg MH; Wirth LJ; Posner M; Wang F
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
Serafini B; Rosicarelli B; Veroni C; Mazzola GA; Aloisi F
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578295
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
37. Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease.
Enblad G; Sandvej K; Lennette E; Sundström C; Klein G; Glimelius B; Pallesen G
Int J Cancer; 1997 Jul; 72(3):394-7. PubMed ID: 9247279
[TBL] [Abstract][Full Text] [Related]
38. Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells : no evidence for the persistence of integrated viral fragments inLatent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease.
Staratschek-Jox A; Kotkowski S; Belge G; Rüdiger T; Bullerdiek J; Diehl V; Wolf J
Am J Pathol; 2000 Jan; 156(1):209-16. PubMed ID: 10623669
[TBL] [Abstract][Full Text] [Related]
39. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
Ning RJ; Xu XQ; Chan KH; Chiang AK
Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
[TBL] [Abstract][Full Text] [Related]
40. EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies.
Yuling H; Ruijing X; Li L; Xiang J; Rui Z; Yujuan W; Lijun Z; Chunxian D; Xinti T; Wei X; Lang C; Yanping J; Tao X; Mengjun W; Jie X; Youxin J; Jinquan T
Cancer Res; 2009 Oct; 69(20):7935-44. PubMed ID: 19808969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
